title: Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).
abstract: BACKGROUND
  There is a continuous need for next-generation non-nucleoside RT inhibitors (NNRTIs) with different resistance profiles, improved safety, excellent tolerability, and favorable physicochemical properties.
  
  
  METHODS
  In this review we intend to narrate a general and cutting-edge overview of current state of NNRTI patents during the 2011-2014 (June) period and future perspectives. Particular focus is placed on the highlighting of some emerging medicinal chemistry principles and insights in the discovery and development of NNRTIs.
  
  
  CONCLUSIONS
  The development of effective NNRTIs is moving on from trial-and-error approaches to sophisticated subconscious strategies. Several newly emerging structure-based virtual screening methodologies (such as Monte Carlo free energy perturbation calculations) or new drug design insights, such as taking full use of the specific noncovalent reverse transcriptase/NNRTIs interactions, stereochemical diversity-oriented conformational restriction, novel strategies to enhance solubility and early absorption, distribution, metabolism, excretion, and toxicity (ADMET) assessment, will continue to evolve to complement the classical NNRTIs discovery approaches (structure-based core-refining and substituents-decorating).
authors.affiliation: Shandong University, School of Pharmaceutical Sciences, Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education) , 44, West Culture Road, 250012, Jinan, Shandong , PR China +86 531 88382005 ; +86 531 88382731 ; zhanpeng1982@163.com , xinyongllab@163.com.
authors.forename: Xiao
authors.initials: X
authors.lastname: Li
authors.forename: Lingzi
authors.initials: L
authors.lastname: Zhang
authors.forename: Ye
authors.initials: Y
authors.lastname: Tian
authors.forename: Yu'ning
authors.initials: Y
authors.lastname: Song
authors.forename: Peng
authors.initials: P
authors.lastname: Zhan
authors.forename: Xinyong
authors.initials: X
authors.lastname: Liu
mesh_terms: D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D008958:Models, Molecular; D010330:Patents as Topic; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase
keywords: AIDS; HIV-1; drug design; inhibitor; medicinal chemistry; non-nucleoside RT inhibitors; patent; reverse transcriptase